Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R E Slayton

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
The Proceedings of the Institute of Medicine of Chicago|April 1, 1980
Management of testicular cancer the role of the medical oncologistR E Slayton
Seminars in Oncology|September 1, 1984
Management of germ cell and stromal tumors of the ovaryR E Slayton
International Journal of Radiation Oncology, Biology, Physics|August 1, 1982
New agents in ovarian cancerR E Slayton
Cancer Treatment Reports|February 1, 1980
Report on drug-induced pericarditisM Ahmed, R E Slayton
Cancer Treatment Reports|September 1, 1981
Progestin therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trialR E Slayton, M Pagano, R H Creech
Cancer Treatment Reports|August 1, 1978
Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomasP D Bonomi, R E Slayton, J Wolter
Cancer Treatment Reports|August 1, 1982
Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyR E Slayton, J A Blessing, G Delgado
Investigational New Drugs|February 1, 1991
A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group studyR E Slayton, J A Blessing, D Clarke-Pearson
Cancer|September 15, 1988
Primary retroperitoneal pure choriocarcinoma. Two long-term complete responders from a rare fatal diseaseJ F Moss, R E Slayton, S G Economou
Cancer|December 1, 1972
Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP)A H Rossof, R E Slayton, C P Perlia
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
The Proceedings of the Institute of Medicine of Chicago|April 1, 1980
Management of testicular cancer the role of the medical oncologistR E Slayton
Seminars in Oncology|September 1, 1984
Management of germ cell and stromal tumors of the ovaryR E Slayton
International Journal of Radiation Oncology, Biology, Physics|August 1, 1982
New agents in ovarian cancerR E Slayton
Cancer Treatment Reports|February 1, 1980
Report on drug-induced pericarditisM Ahmed, R E Slayton
Cancer Treatment Reports|September 1, 1981
Progestin therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trialR E Slayton, M Pagano, R H Creech
Cancer Treatment Reports|August 1, 1978
Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomasP D Bonomi, R E Slayton, J Wolter
Cancer Treatment Reports|August 1, 1982
Phase II trial of etoposide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyR E Slayton, J A Blessing, G Delgado
Investigational New Drugs|February 1, 1991
A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group studyR E Slayton, J A Blessing, D Clarke-Pearson
Cancer|September 15, 1988
Primary retroperitoneal pure choriocarcinoma. Two long-term complete responders from a rare fatal diseaseJ F Moss, R E Slayton, S G Economou
Cancer|December 1, 1972
Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP)A H Rossof, R E Slayton, C P Perlia
Pageof 4